55575
document
The in vitro effects of verbascoside on human platelet aggregation . Preliminary in vitro and animal studies have shown that verbascoside , a phenolic compound , may have several favourable biological activities , including an influence on endothelial function and on platelet aggregation . We sought to evaluate the effects of verbascoside , biotechnologically produced from plant cell cultures , on human platelet aggregation ( PA ) . The blood from 40 aspirin-naïve volunteers with at least one cardiovascular risk factor was preincubated in vitro with verbascoside ( 1 and 2 mg/dL ) and aspirin ( 100 μM ) . The blood from 20 patients with a prior diagnosis of coronary heart disease who were chronically assuming aspirin was preincubated in vitro with verbascoside ( 1 and 2 mg/dL ) . PA is measured with a light transmission aggregometry and multiplate analyzer . As compared to reference , preincubation with verbascoside resulted in a significant inhibition of adenosine diphosphate ( ADP ) and arachidonic acid ( AA ) -induced PA ( p < 0.01 for both ) . Verbascoside 2 mg/dL did not show a stronger effect as compared to verbascoside 1 mg/dL ( p = 0.4 ) . As expected , the in vitro addition of aspirin reduced AA induced PA ( p < 0.01 ) , but not that induced by ADP ( p = 0.5 ) . The addition of verbascoside to the blood of aspirin-treated patients did not improve the values of PA after AA stimulus ( p = 0.8 ) , whereas it ensured a stronger inhibition after ADP stimulus ( p < 0.01 ) . Verbascoside in vitro affects PA by mildly inhibiting aggregation , triggered both by ADP and AA . These preliminary data , while intriguing , require confirmation in subjects receiving verbascoside orally in order to determine whether these findings are clinically relevant .
55576
Intervention_Pharmacological
verbascoside
55577
Intervention_Pharmacological
verbascoside
55578
Intervention_Pharmacological
verbascoside
55579
Outcome_Physical
significant inhibition of adenosine diphosphate ( ADP )
55580
Outcome_Physical
values of PA
55581
Participant_Condition
human platelet aggregation .